Results 181 to 190 of about 310,786 (327)
Parabiosis, Assembloids, Organoids (PAO)
This review evaluates parabiosis, organoids, and assembloids as complementary disease models spanning systemic, organ, and multi‐organ levels. It highlights their construction strategies, applications, and current limitations, while emphasizing their integration with frontier technologies such as artificial intelligence, organ‐on‐a‐chip, CRISPR, and ...
Yang Hong +5 more
wiley +1 more source
A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4
This work identifies CD3.NKp46.CD19.NK1.1. NK‐B cells enriched in PDK1‐deficient yet present in wild‐type bone marrow. IL‐15 (via CD122) and TLR9‐microbiota signaling maintain their E4BP4 expression. These cells demonstrate innate immunity, preferentially differentiate into B cells, and unveil a novel microbiota‐ and IL‐15‐dependent regulatory pathway ...
Junming He +11 more
wiley +1 more source
Chemotherapy‐induced efferocytosis drives ovarian cancer stem cell enrichment. By engulfing apoptotic cancer cells, macrophages upregulate ODC1 and produce putrescine, which elevates osteopontin (OPN) expression. Secreted OPN then activates the CD44 receptor on cancer cells, promoting stemness and chemoresistance.
Wenhan Li +19 more
wiley +1 more source
METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation
METTL5 reshapes the tumor immune microenvironment through ribosome 18S rRNA m6A modification to regulate the translation of chemokine mRNA. Targeting METTL5‐mediated immunosuppression unleashes anti‐tumor immunity and improves the efficacy of anti‐PD‐1 therapy.
Shuang Li +19 more
wiley +1 more source
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? [PDF]
Pawel Muranski +6 more
openalex +1 more source
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu +34 more
wiley +1 more source

